Research Topics
| Bharat DamleSummaryAffiliation: Pfizer Global Research and Development Country: USA Publications
| Collaborators
|
Detail Information
Publications
Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential useBharat Damle
Pfizer Inc, New York, New York 10017, USA
Antimicrob Agents Chemother 55:5172-7. 2011..Frequent monitoring for voriconazole-related adverse events is advisable if voriconazole is used sequentially after fluconazole...- Lack of an effect of standard and supratherapeutic doses of linezolid on QTc interval prolongationBharat Damle
Pfizer, Inc, 235 East 42nd St, New York, NY 10017, USA
Antimicrob Agents Chemother 55:4302-7. 2011.... - Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanismKuan Gandelman
Pfizer Inc, 235 East 42nd St, New York, NY 10017, USA
J Clin Pharmacol 51:229-36. 2011..The clinical significance of the decreased linezolid levels is unclear. Linezolid and rifampin administered alone or in combination was generally safe and well tolerated... - Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metaboliteBharat D Damle
Pfizer Inc, Global Medical Research and Development, 685 Third Avenue, 685 13 55, New York, NY 10017, USA
Br J Clin Pharmacol 68:682-9. 2009.... - Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT studyBharat Damle
Pfizer Global Research and Development, Pfizer Inc, 685 Third Ave, 685 13 55, New York, NY 10017, USA
J Clin Pharmacol 49:291-300. 2009..At clinically relevant, doses nelfinavir is unlikely to cause QTc prolongation... - Pharmacokinetics and tissue distribution of anidulafungin in ratsBharat Damle
Pfizer Inc, New York, New York 10017, USA
Antimicrob Agents Chemother 52:2673-6. 2008..In tissues susceptible to fungal infection (liver, lung, spleen, kidney), exposure was 9- to 12-fold higher than in plasma... - Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteersBharat Damle
Clinical Pharmacology, Pfizer Global Research and Development, New York, NY 10017, USA
Br J Clin Pharmacol 65:523-30. 2008..Furthermore, voriconazole increases the systemic exposure of efavirenz. * Co-administration was therefore initially contraindicated... - Pharmacokinetics of nelfinavir in subjects with hepatic impairmentBharat Damle
Pfizer Global Research and Development, Pfizer Inc, New York, NY 10017, USA
J Clin Pharmacol 46:1241-9. 2006..Further long-term evaluations of nelfinavir pharmacokinetics and safety in HIV-seropositive subjects with hepatic impairment may be useful... - Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairmentJames A Dowell
Vicuron Pharmaceuticals, Inc, New York, NY, USA
J Clin Pharmacol 47:461-70. 2007..Anidulafungin can be safely administered to patients with any degree of hepatic or renal impairment without dosage adjustment and without regard to hemodialysis schedules... - Lack of pharmacokinetic interaction between anidulafungin and tacrolimusJames A Dowell
Clinical Pharmacology, Pfizer Global Research and Development, 685 3rd Avenue, New York, NY 10017, USA
J Clin Pharmacol 47:305-14. 2007..Because of its lack of pharmacokinetic interaction with key immunosuppressive agents, anidulafungin is an important option for the prevention and treatment of invasive fungal infections in transplant recipients... - Assessment of the pharmacokinetics of co-administered maraviroc and raltegravirEmma Andrews
Pfizer Inc, New York, NY, USA
Br J Clin Pharmacol 69:51-7. 2010..However, unexpected interactions have been reported for other antiretroviral drugs. * As both these drugs are likely to be used in combination, this study evaluated the pharmacokinetic interaction between them... - Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD)David R Luke
Pfizer, Inc, New York, New York, USA
J Pharm Sci 99:3291-301. 2010..Nonetheless, serum creatinine levels should be monitored in subjects with renal compromise receiving multiple doses of SBECD... - Pharmacokinetics of sulfobutylether-?-cyclodextrin (SBECD) in subjects on hemodialysisDavid R Luke
Infectious Diseases, Pfizer Inc, Collegeville, PA, USA
Nephrol Dial Transplant 27:1207-12. 2012..v.) voriconazole, was assessed in seven male subjects with end-stage renal disease on hemodialysis and six subjects with normal renal function... - Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjectsPing Ji
Bristol Myers Squibb Research and Development, Mail Stop E1215, Route 206 and Province Line Road, Princeton, NJ 08543, USA
J Clin Pharmacol 48:948-56. 2008..99 [0.85-1.15]; C(max), 1.05 [0.91, 1.22]). In summary, a 2-way pharmacokinetic interaction between efavirenz and carbamazepine was demonstrated in this study... - Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignanciesQuincy Siu-Chung Chu
Institute for Drug Development, Cancer Therapy and Research Center and The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
Clin Cancer Res 10:4913-21. 2004.... - Pharmacokinetics and gamma scintigraphy evaluation of two enteric coated formulations of didanosine in healthy volunteersBharat Damle
Bristol Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA
Br J Clin Pharmacol 54:255-61. 2002.... - Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected childrenJennifer R King
The University of Alabama at Birmingham, Birmingham, Ala, USA
Antivir Ther 7:267-70. 2002.... - Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five daysJame Abraham
Mary Babb Randolph Cancer Center, West Virginia University, Morgantown, USA
J Clin Oncol 21:1866-73. 2003..Neutropenia was dose limiting, but higher doses were tolerated by a large fraction of patients with filgrastim support. Peripheral neuropathy was mild, even after multiple cycles of therapy, and was not dose limiting... - Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403Jennifer R King
University of Alabama at Birmingham, Birmingham, USA
Pediatr Infect Dis J 24:880-5. 2005..Differences in tolerability between the 2 treatment groups were not identified. Systemic exposure of these drugs was similar to that reported in other HIV-infected children and adults... - Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancerSteven J Cohen
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 8:2116-22. 2002..Evaluation of once-daily dosing of S-1 in malignancies for which fluoropyrimidines have known antitumor activity is warranted...